Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 9/20 | 0.70 |
| ▸ | MAP4K2 | Q12851 | 9/20 | 0.70 |
| ▸ | ABL1 | P00519 | 2/20 | 0.70 |
| ▸ | BCR | P11274 | 1/20 | 0.70 |
| ▸ | BMX | P51813 | 1/20 | 0.70 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.70 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.70 |
| ▸ | BTK | Q06187 | 1/20 | 0.66 |
| ▸ | JAK2 | O60674 | 10/20 | 0.63 |
| ▸ | JAK1 | P23458 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 8/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18181601 | 0.97 | TNK2 (0.68) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL18181534 | 0.90 | BTK (0.81) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL18171854 | 0.88 | TNK2 (0.71) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL18181608 | 0.88 | TNK2 (0.72) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL3130257 | 0.85 | TNK2 (0.85) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL21479267 | 0.85 | TNK2 (0.75) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL18171855 | 0.85 | BTK (0.73) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL18181684 | 0.83 | BTK (0.70) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL30276313 | 0.83 | BTK (0.70) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL18181552 | 0.83 | BTK (0.70) | TNK2MAP4K2ABL1BCRBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364247-B2 | Preparation and use of novel protein kinase inhibitors | RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2019-07-30 | — | — | US | disclosed |
| US-20180105528-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | BRANDEIS UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| WO-2016168992-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016168992-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364247-B2 | Preparation and use of novel protein kinase inhibitors | MAP3K20, MAP3K19, MAP3K5 | TNK2 31/4885MAP4K2 12/4885ABL1 103/4885 |
| US-20180105528-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K5 | TNK2 31/4885MAP4K2 12/4885ABL1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.